Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Michael Bogenstaetter as chief business officer

He joins the immuno-oncology biotech from Interim Assignments

Michael BogenstaetterNorwegian biotechTargovax has appointed its new chief business officer in the form of Michael Bogenstaetter, who joins following 25 years’ experience in the biotech and pharmaceutical industries.

Bogenstaetter previously served as an advisor of life sciences and health care at Interim Assignments, and before that he served as global head strategy, project management and operations drug discovery at Sanofi.

He has also held numerous roles for Novartis, MSD and Johnson and Johnson.

Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”

22nd January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics